.png){kind=icon}
-
Rescuing Patient Enrollment for a Study of a Rare Mutation
Case StudiesJun. 30, 2020
A midsized pharmaceutical company was developing a treatment targeting newly diagnosed acute myeloid leukemia (AML) patients and selected Covance to support their global Phase III trial. Using LabCorp de-identified clinical laboratory data helped the planning teams locate difficult to find patients and increase recruitment.
A midsized pharmaceutical company was developing a treatment targeting newly diagnosed acute myeloid leukemia (AML) patients and selected Covance to support their global Phase III trial. Using LabCorp de-identified clinical laboratory data helped the planning teams locate difficult to find patients and increase recruitment.
